[Clinico-immunological effectiveness of likopid in conservative treatment of patients with chronic tonsillitis and chronic sinusitis]. 2001

S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva

30 patients with chronic tonsillitis (CT) and 20 patients with chronic sinusitis (CS) received likopid (4 mg/day for 10 days). CT patients were additionally treated with tonsil lacunar lavage with dioxidine solution. Likopid was found effective in CT patients (good response--31%, partial response--59%). 9% did not respond to likopid. CS patients benefited less (good response--10%, partial response--50%). 40% were non-responders. In CT patients likopid demonstrated also an immunomodulating effect. Positive changes were observed in the counts of B-lymphocytes, T-lymphocytes, T-helpers, natural killers, level of serum IgG, titers of specific antibodies, functional activity of neutrophils. In CS this effect was less pronounced.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000119 Acetylmuramyl-Alanyl-Isoglutamine Peptidoglycan immunoadjuvant originally isolated from bacterial cell wall fragments; also acts as pyrogen and may cause arthritis; stimulates both humoral and cellular immunity. Mur-NAc-L-Ala-D-isoGln,Muramyl Dipeptide,Acetylmuramyl Alanyl Isoglutamine,N-Acetyl-Muramyl-L-Alanyl-D-Glutamic-alpha-Amide,N-Acetylmuramyl-L-Alanyl-D-Isoglutamine,Alanyl Isoglutamine, Acetylmuramyl,Dipeptide, Muramyl,Isoglutamine, Acetylmuramyl Alanyl,Mur NAc L Ala D isoGln,N Acetyl Muramyl L Alanyl D Glutamic alpha Amide,N Acetylmuramyl L Alanyl D Isoglutamine
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012852 Sinusitis Inflammation of the NASAL MUCOSA in one or more of the PARANASAL SINUSES. Sinus Infections,Infection, Sinus,Infections, Sinus,Sinus Infection,Sinusitides

Related Publications

S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
January 1998, Terapevticheskii arkhiv,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
January 1984, Vestnik otorinolaringologii,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
January 1969, Vestnik otorinolaringologii,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
January 1973, Vestnik otorinolaringologii,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
January 1978, Terapevticheskii arkhiv,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
September 1973, Pediatriia,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
January 1969, Vestnik otorinolaringologii,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
January 1970, Vestnik otorinolaringologii,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
November 1975, Zeitschrift fur Allgemeinmedizin,
S V Filatova, and B V Pinegin, and A V Simonova, and M E Artem'ev, and N M Golubeva
January 1972, Vestnik otorinolaringologii,
Copied contents to your clipboard!